Brainsway Q2 2025 Earnings Report

Brainsway EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.07
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Brainsway Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $12.34 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Brainsway Announcement Details

• Quarter: Q2 2025
• Date: 8/5/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Brainsway (NASDAQ:BWAY) (NASDAQ: BWAY) is an Israeli medical device company headquartered in Jerusalem that specializes in designing, developing and marketing non-invasive neurostimulation technologies for the treatment of psychiatric and neurological disorders. Founded in 2003, the company’s core mission is to provide safe, drug-free alternatives for patients who have shown inadequate response to conventional therapies.

The company’s flagship offering is the Deep Transcranial Magnetic Stimulation (Deep TMS) system, which utilizes patented H-coil technology to deliver magnetic pulses to specific brain regions. Deep TMS has received U.S. Food and Drug Administration clearances for treatment-resistant depression, obsessive-compulsive disorder and nicotine dependence. Beyond its approved indications, Brainsway is advancing a pipeline of coil configurations and treatment protocols targeting conditions such as anxiety, post-traumatic stress disorder and chronic pain.

Brainsway maintains a global footprint, with direct sales operations and distribution partnerships across North America, Europe, Asia-Pacific and Israel. The company collaborates with leading academic institutions and clinical centers to conduct pivotal trials and expand the scientific evidence supporting its therapies. A dedicated network of clinical trainers and technical service teams ensures healthcare providers receive comprehensive support for implementing and maintaining Deep TMS systems in hospitals, outpatient clinics and specialized treatment centers.

Since its initial public offering on the Nasdaq, Brainsway has steadily grown its installed base of Deep TMS systems while securing broader reimbursement coverage and forging strategic alliances. Under the leadership of Chief Executive Officer Ohad Tal and a management team with deep expertise in medical technology and neuroscience, Brainsway continues to invest in research and development. The company’s ongoing efforts focus on enhancing its existing product portfolio and exploring new applications for non-invasive brain stimulation in mental health and neurological care.